Zai Lab Limited (HKG:9688)
14.22
-0.18 (-1.25%)
Jul 30, 2026, 12:00 PM HKT
Zai Lab Employees
Zai Lab had 1,784 employees as of December 31, 2025. The number of employees decreased by 85 or -4.55% compared to the previous year.
Employees
1,784
Change (1Y)
-85
Growth (1Y)
-4.55%
Revenue / Employee
1.99M HKD
Profits / Employee
-782.75K HKD
Market Cap
16.14B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,784 | -85 | -4.55% | 1,784 | 0 |
| Dec 31, 2024 | 1,869 | -306 | -14.07% | 1,869 | 0 |
| Dec 31, 2023 | 2,175 | 139 | 6.83% | 2,175 | 0 |
| Dec 31, 2022 | 2,036 | 85 | 4.36% | 2,036 | 0 |
| Dec 31, 2021 | 1,951 | 757 | 63.40% | 1,951 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Shanghai Henlius Biotech | 3,762 |
| Keymed Biosciences | 1,625 |
| InnoCare Pharma | 1,176 |
| Ascentage Pharma Group International | 767 |
| HBM Holdings | 272 |
| Duality Biotherapeutics | 231 |
| Ascletis Pharma | 202 |
Zai Lab News
- 7 days ago - Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 - Business Wire
- 5 weeks ago - Insider Sell Alert: William Lis Sells 7,040 Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 6 weeks ago - Zai Lab Transcript: AGM 2026 - Transcripts
- 6 weeks ago - Zai Lab announces EMA granted ODD to zocilurtatug pelitecan - TheFly
- 6 weeks ago - Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas - Business Wire
- 7 weeks ago - Zai Lab (ZLAB) Gains Approval for Tivdak in Cervical Cancer Treatment - GuruFocus
- 7 weeks ago - Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
- 2 months ago - Zai Lab (ZLAB) Q1 2026 Earnings Transcript - The Motley Fool